Mymetics Corp (MYMX)

[Work Harder]

Recent Progress on the Versatility of Virus-Like Particles

https://www.mdpi.com/2076-393X/8/1/139/htm

5.2. VLP-Based Vaccine versus Virosomes-Based Vaccine

Virosomes, a spherical, unilamellar vesicles with a mean diameter of ~150 nm, and without nucleocapsid and genetic material of the source virus, are also used as important delivery tools in vaccine development [109,110]. Similar to VLPs, virosomes have repetitive epitopes and special envelope vesicle structure, can activate the immune response [111], and serve as vectors to display foreign antigens that are fused on the surface or inserted into a double bilayer [110]. Additionally, virosomes can be used as vaccine adjuvants to enhance the immunogenicity. A virosome-formulated vaccine, Epaxal, based on formalin-inactivated HAV (strain RG-SB), has proven that in the absence of aluminum hydroxide adjuvant, a single injection is well-tolerated and highly immunogenic, with 88%–97% of seroprotection [112]. Therefore, virosomes are also a promising vaccine adjuvant or delivery vehicle.